BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2026 1:50:33 AM | Browse: 2 | Download: 3
 |
Received |
|
2026-03-23 00:48 |
|
Peer-Review Started |
|
2026-03-23 00:48 |
|
First Decision by Editorial Office Director |
|
2026-05-20 09:21 |
|
Return for Revision |
|
2026-05-20 09:21 |
|
Revised |
|
2026-06-12 23:52 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-07-02 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-02 08:35 |
|
Articles in Press |
|
2026-07-02 08:35 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-21 06:58 |
|
Publish the Manuscript Online |
|
2026-09-30 01:50 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Advanced therapies in patients with inflammatory bowel disease: A nationwide population-based cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hyoung Il Choi, Jung Rock Moon, Sun Hwa Lee and Jae Myung Cha |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| BongHwa Scholarship Foundation to the Korean Association for the Study of Intestinal Diseases for 2024 |
|
|
| Corresponding Author |
Jae Myung Cha, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, South Korea. drcha@khu.ac.kr |
| Key Words |
Biological products; Crohn’s disease; Inflammatory bowel disease; Ulcerative colitis; Treatment pathway |
| Core Tip |
This nationwide Korean study demonstrates that advanced therapy use for inflammatory bowel disease shows distinct patterns between Crohn’s disease and ulcerative colitis. Anti-tumor necrosis factor agents, particularly infliximab, are the most common first-line treatments, with earlier initiation and longer persistence in Crohn’s disease. In contrast, vedolizumab is more frequently used for ulcerative colitis, and ustekinumab more commonly used for Crohn’s disease. Overall, treatment sequencing and durability differed significantly according to disease subtype, highlighting the importance of tailored, disease-specific therapeutic strategies in real-world clinical practice. |
| Publish Date |
2026-09-30 01:50 |
| Citation |
Choi HI, Moon JR, Lee SH, Cha JM. Advanced therapies in patients with inflammatory bowel disease: A nationwide population-based cohort study. World J Gastroenterol 2026; 32(44): 121290
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i44/121290.htm |
| DOI |
https://doi.org/10.3748/wjg.121290 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
